Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 295 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Inhaler Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

NCT00094016
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
37
States / cities
Huntington Beach, California • Long Beach, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

NCT06067828
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Tarzana, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01694771
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
90
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
View directory record Official record
Conditions
COPD
Interventions
indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

NCT00392288
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 11 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 20, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

NCT06018766
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions
LAM-001, Placebo
Drug
Lead sponsor
Steven Hays, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
14
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

NCT00467740
View directory record Official record
Conditions
Asthma
Interventions
BI 1744 CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
10
States / cities
Lakewood, California • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 20, 2026, 5:37 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 5:37 PM EDT